Mar. 10 at 3:19 PM
The B2i Digital team is pleased to announce that Phio Pharmaceuticals Corp. (Nasdaq:
$PHIO), a B2i Digital Featured Company, is participating in the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, on Thursday, March 12, 2026, at 11:00 AM EDT.
The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/otc-life-sciences-virtual-investor-forum
For the full B2i Digital profile of Phio Pharmaceuticals, please visit: https://b2idigital.com/phio-pharmaceuticals-corp-1
Virtual Investor Conferences brings together public companies and a global audience of retail and institutional investors for live executive presentations, Q&A sessions, and on-demand replays. The platform is open to public companies listed on NYSE, Nasdaq, TSX, CSE, ASX, and the OTC Markets.
Phio Pharmaceuticals is developing therapeutics using INTASYL, a chemically modified siRNA technology designed to silence specific genes that hinder the immune system’s ability to fight cancer, with a focus on immuno-oncology. Unlike many siRNA approaches that rely on complex delivery systems such as lipid nanoparticles, INTASYL compounds are engineered to self-deliver into cells without additional formulations, simplifying administration and potentially reducing toxicity.
Presenting on behalf of Phio Pharmaceuticals will be Robert Bitterman, President and Chief Executive Officer. Mr. Bitterman has served on the company’s board since 2012 and assumed his current role in February 2023. He previously founded and served as President and CEO of Cutanea Life Sciences, a company focused on innovative treatments for diseases of the skin, until its acquisition by Biofrontera in 2019. Earlier in his career he held executive roles at Isolagen and Dermik Laboratories and various positions at Aventis. He holds an A.B. in Economics from the College of the Holy Cross and an MBA from Boston University.
To register for this presentation, visit: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5269944/phio-pharmaceuticals-corp-nasdaq-phio?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC
For more information about Phio Pharmaceuticals, visit: https://phiopharma.com/investors/
Content about any specific company was provided and approved by that company or is available in the public domain. B2i Digital, Inc. has not independently verified the accuracy of the information contained herein. The content contained herein is informational only, and no content contained herein shall be considered an offer to solicit the sale of any security or make a recommendation to purchase a security. B2i Digital is not a broker-dealer or investment adviser.
